Polskie Archiwum Medycyny Wewnętrznej
-
Pol. Arch. Med. Wewn. · Jan 2010
Randomized Controlled TrialThe influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease.
There is growing evidence that chronic obstructive pulmonary disease (COPD) is a risk factor for coronary heart disease. Simvastatin is a hypolipemic drug with proven efficacy in the prevention of cardiovascular diseases. Observational studies showed that statins may be useful in the reduction of mortality from COPD. Experimental studies on animals showed anti-inflammatory effects of statins on the lung tissue. ⋯ In COPD patients, a 3-month treatment with simvastatin does not reduce circulating inflammatory markers.